1. Conflation of somatic tumor genetics with host pharmacogenetics (Section 6 & Figure 5). You discuss TP53 and ATM mutations as genetic predictors of chemotherapy-induced toxicity (e.g., neutropenia, mucositis). However, the vast majority of TP53 mutations are somatic (confined to the tumor), whereas host toxicity (myelosuppression, GI damage) is overwhelmingly determined by germline genetics and pharmacokinetics. How do you mechanistically justify that a somatic mutation in malignant cells directly dictates the tolerability of normal, proliferating tissues (bone marrow and gut)? Citing rare germline Li-Fraumeni cases does not excuse the broad and misleading application to general oncology patients.
2. Overstatement of clinical utility for ABCB1 and ERCC1 markers (Table 1). In Table 1, you state that ABCB1 variants (C3435T, G2677T/A) may require higher doses or alternative therapies and that ERCC1 variants imply resistance to platinum-based chemotherapy. These markers have no CPIC (Clinical Pharmacogenetics Implementation Consortium) or ASCO clinical guidelines supporting their routine use due to conflicting prospective evidence. Presenting them as actionable without explicitly highlighting the lack of validation and contradictory literature is misleading. Why did you choose to omit this critical caveat in your clinical implications?